Drug/Diagnostic Partnerships Fueled By Promise Of Reduced Trial Costs
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic manufacturers should be careful to keep their alliances with drug companies open enough to accommodate pharmacogenomic advances, panelists agreed at Thomas Weisel Partners' Healthcare Tailwinds 2002 meeting in Boston April 29
You may also be interested in...
Pharmacogenomic Progress Hinges On Strong Pharma Backing – Consultant
Reference labs developing less costly "homebrew" tests could supplant diagnostic firms as the vehicle for commercializing pharmacogenomic tests, consultant Richard Barker told attendees at the IBC Dx/Rx Summit March 9 in Reston, Va
Pharmacogenomic Progress Hinges On Strong Pharma Backing – Consultant
Reference labs developing less costly "homebrew" tests could supplant diagnostic firms as the vehicle for commercializing pharmacogenomic tests, consultant Richard Barker told attendees at the IBC Dx/Rx Summit March 9 in Reston, Va
Test Would Assess Risk Of Cardiovascular Disease Using Enzyme’s Presence
diaDexus and GlaxoSmithKline are in the early stages of developing a joint diagnostic and therapeutic approach to treat patients by detecting and inhibiting an enzyme that may predict instances of cardiovascular disease